LONDON UK. Cellnovo
today announced both the commercial launch of the world’s only mobile-connected
diabetes management system, and the start of the largest usability trial ever
to investigate insulin pump technology for patients with type 1 diabetes. The trial
will also be the first in which all clinical data is captured remotely, in
real-time; using the mobile data connectivity of the Cellnovo system.
Cellnovo’s diabetes management system comprises an insulin
pump that connects wirelessly to an intuitive ‘app-based’ touch-screen handset.
The handset features an integral blood glucose monitor, an activity monitor and
a mobile (GSM) data connection to a comprehensive web-based clinical management
Cellnovo patients will be able to track and manage their
diabetes; securely sharing all clinical information through the web so that
they, their doctors, nurses and family members can ensure sustained and
effective diabetic control.
Principal Investigator of the Cellnovo usability trial, and
world-leading authority on insulin pump therapy, Professor John Pickup of
King’s College London School of Medicine, remarked, “This clinical trial
is not just the world’s first with a mobile-connected insulin infusion system,
it is also the first clinical trial in which the care team and patients can
simultaneously observe and evaluate patient data in real-time, anywhere in the
Co-trialist, Dr Mark Evans of Addenbrookes Hospital in
Cambridge, commented, “This technology represents a entirely new model for
the management of diabetes and one that could be of direct and long-term
financial benefit to the NHS. The effective management of diabetes requires
masses of information. The more information we have, and the more rapidly we
have it, the better job we can do of using our resources efficiently to prevent
the devastating long-term complications of diabetes. The Cellnovo system is the
world’s first both to automate and deliver instantly the information we need ?
a task achieved through the thoughtful and thorough integration of consumer
technology, such as wireless and cellular, with medical sensor and precision
Co-trialist, Professor Stephen Greene of the University of Dundee added, “The Cellnovo system
provides us immediate access to the clinical status of all our patients on a
single screen. With accurate and current information we can identify and
address problems immediately that, otherwise, might go unnoticed for months,
contributing to excess cost and potentially tragic patient complications. In
this clinical trial we will be the first to explore these new opportunities in
diabetes patient management and hope to uncover new ways to improve and extend
care, optimise workflow and drive cost efficiencies.”
William F. McKeon, Cellnovo Chief Executive Officer added,
“The launch of the Cellnovo system marks a new era in medicine where
mobile connectivity is routinely embedded in medical devices. We draw upon the
convenience of mobile technology in so many aspects of our lives: email, photos,
social networking and banking. It is now time that our most precious asset, our
health, benefits from the real-time information flow that is made possible with
an in-built mobile connection. We are moving into an era where our doctors will
routinely detect health issues over the web, before they worsen; and where
patients and family members have the peace of mind that dangerous and costly
emergencies can be avoided as early signs are immediately spotted.”
“The Cellnovo usability trial will be conducted in ten
of the leading diabetes centers across the UK and will involve 100 patients,
both adults and children. Such scale is unprecedented for a trial of insulin
infusion technology and its usability.” concluded Dr Reman McDonagh,
Director of Clinical and Physician Relations for Cellnovo.
Type 1 diabetes is routinely managed with pump technology
throughout much of Europe and North America
where 20-25% of patients gain benefit from therapy that mimics the body?s
normal production of insulin. Yet the UK lags behind, with 96% of
patients having to rely on multiple daily injections. By introducing a unique
system that uses cellular data and touch screen technology, Cellnovo aims to
eliminate the barriers to adoption of insulin pump therapy; simplifying and
reducing the workload for doctors and nurses, while also improving the quality
of insight and diabetes management achieved by patients.
Type 1 diabetes affects 250,000 UK patients for whom the prospect
of poor diabetic control can lead to blindness, nerve damage and death. Caring
for diabetes accounts for 10% of the NHS budget, a significant proportion of
which is focused on type 1, a growing challenge that affects 4% more UK patients
each year. Type 1 diabetes can only be managed by the daily or constant
administration of insulin, replacing the role of the pancreas that for these
patients has become incapable of producing insulin, which is vital for the
metabolism of carbohydrates.
Cellnovo is a mobile medical device company based in London, UK.
The company was built by a seasoned group of veterans from both the medical
device and mobile communications industries. Together, they have developed a
mobile health system designed to reduce burden and provide more insight to
people with diabetes, their healthcare teams and families.
The number of people with diabetes is estimated to double in
the next twenty years, placing a tremendous strain on all healthcare systems
throughout the world. The Cellnovo mobile diabetes management system is
transformational in that it provides real-time access to patient data and the
opportunity to streamline and improve care while at the same time reduce costs.
For more information, please visit http://www.cellnovo.com.